These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 38818582)
1. COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma. Zhang S; Xue X; Chen F; Yang Y; Zhang N; Chen Y; Wu W; Wang J; Zheng N Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(7):997-1010. PubMed ID: 38818582 [TBL] [Abstract][Full Text] [Related]
2. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT. Zhang N; Zhang S; Wu W; Lu W; Jiang M; Zheng N; Huang J; Wang L; Liu H; Zheng M; Wang J Mol Carcinog; 2021 Feb; 60(2):151-163. PubMed ID: 33428809 [TBL] [Abstract][Full Text] [Related]
3. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078 [TBL] [Abstract][Full Text] [Related]
4. CircDCAF8 promotes the progression of hepatocellular carcinoma through miR-217/NAP1L1 Axis, and induces angiogenesis and regorafenib resistance via exosome-mediated transfer. Gong J; Han G; Chen Z; Zhang Y; Xu B; Xu C; Gao W; Wu J J Transl Med; 2024 May; 22(1):517. PubMed ID: 38816735 [TBL] [Abstract][Full Text] [Related]
5. CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells. Pan Y; You B; Zhao X; Zhang S; Li W BMC Cancer; 2024 Apr; 24(1):525. PubMed ID: 38664644 [TBL] [Abstract][Full Text] [Related]
6. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791 [TBL] [Abstract][Full Text] [Related]
7. The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. Kuang S; Zhang J; Huang N; Zhang J; Chen B; Wang L; Liu M Mol Carcinog; 2024 Sep; 63(9):1738-1749. PubMed ID: 38837427 [TBL] [Abstract][Full Text] [Related]
8. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Ma WL; Hsu CL; Yeh CC; Wu MH; Huang CK; Jeng LB; Hung YC; Lin TY; Yeh S; Chang C Hepatology; 2012 Jul; 56(1):176-85. PubMed ID: 22318717 [TBL] [Abstract][Full Text] [Related]
9. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107 [TBL] [Abstract][Full Text] [Related]
10. Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. Takuma K; Fujihara S; Fujita K; Iwama H; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Shi T; Morishita A; Kobara H; Himoto T; Masaki T Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163589 [TBL] [Abstract][Full Text] [Related]
11. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma. Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809 [TBL] [Abstract][Full Text] [Related]
12. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance. Huang H; Hou J; Liu K; Liu Q; Shen L; Liu B; Lu Q; Zhang N; Che L; Li J; Jiang S; Wang B; Wen Q; Hu L; Gao J J Gastroenterol Hepatol; 2021 Dec; 36(12):3429-3437. PubMed ID: 34258777 [TBL] [Abstract][Full Text] [Related]
13. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235 [TBL] [Abstract][Full Text] [Related]
14. Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429-dependent m6A modification of CCR9. Lv Z; Liu L; You J; Zhou P; Su Y; Zhao K; Zhang J; Zhu F J Med Virol; 2024 Sep; 96(9):e29894. PubMed ID: 39206838 [TBL] [Abstract][Full Text] [Related]
15. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422 [TBL] [Abstract][Full Text] [Related]
16. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Kabir TD; Ganda C; Brown RM; Beveridge DJ; Richardson KL; Chaturvedi V; Candy P; Epis M; Wintle L; Kalinowski F; Kopp C; Stuart LM; Yeoh GC; George J; Leedman PJ Hepatology; 2018 Jan; 67(1):216-231. PubMed ID: 28833396 [TBL] [Abstract][Full Text] [Related]
17. Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma. Ou H; Chen Z; Xiang L; Fang Y; Xu Y; Liu Q; Hu Z; Li X; Huang Y; Yang D Cancer Sci; 2019 Apr; 110(4):1169-1182. PubMed ID: 30677195 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413 [TBL] [Abstract][Full Text] [Related]
19. Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). Yang Q; Guo X; Yang L Med Sci Monit; 2018 Apr; 24():2225-2234. PubMed ID: 29654226 [TBL] [Abstract][Full Text] [Related]
20. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]